Ryvyl Inc. Common Stock
RVYLRyvyl Inc. (RVYL) is a biotechnology company focused on advancing regenerative medicine and tissue engineering technologies. The company develops innovative solutions to improve tissue repair and wound healing, aiming to address unmet medical needs in healthcare.
Company News
RYVYL Inc. (NASDAQ: RVYL) announced board approval of a 1-for-35 reverse stock split, effective January 1, 2026, to increase the stock price and maintain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will consolidate every 35 shares into one share, with trading resuming on a split-adjusted basis on January 2, 202...
RYVYL has rescheduled its 2025 Annual Meeting to December 15, 2025, to accommodate new shareholders following its merger agreement with Roundtable Digital, a Web3 digital media SaaS technology company.
U.S. stock futures declined on Wednesday following a government shutdown, with major indices experiencing premarket drops. Despite the shutdown, historical data suggests limited long-term market impact, and analysts remain cautiously optimistic about market performance in October.
Ryvyl announced a merger with RTB Digital, a Web3 digital media SaaS technology company, with a $41.25 million pre-money enterprise value. The transaction will result in Ryvyl shareholders owning 15.15% of the combined company and pursuing a Bitcoin treasury strategy.
RYVYL's Chairman and Co-founder Ben Errez is retiring on August 31, 2025. The company is repositioning its business to focus on crypto treasury management, viewing digital assets as a long-term store of value and strategy for financial resilience.
